Vascular complications are major causes of morbidity and mortality in diabetic patients. Recently, our group identified a novel purinergic signaling pathway involving the P2Y11/AKAP5/AC5/PKA/CaV1.2 protein network in arterial myocytes. This purinergic complex is activated by the release of nucleotides (e.g. ATP) to the extracellular space in response to hyperglycemic conditions, which promotes L‐type CaV1.2 potentiation and vasoconstriction. Pannexin 1 (Panx1) is a channel that mediates ATP efflux, thus inducing purinergic signaling activation. However, whether Panx1 forms part of the novel purinergic signaling complex that regulates L‐type CaV1.2 activity and vascular reactivity during diabetic hyperglycemia is unknown. Here, we find that Panx1 is in complex with P2Y11, AKAP5, AC5, PKA and CaV1.2 in arterial myocytes. This protein complex is strengthened upon elevated glucose (HG) treatment. However, the Panx1 inhibitor spironolactone prevented the HG‐induced strengthening of the complex. Spironolactone also blocked cAMP production, L‐type CaV1.2 potentiation and sustained vasoconstriction in response to elevated glucose. Consistent with a role for Panx1 upstream of P2Y11, spironolactone failed to prevent HG‐induced vasoconstriction upon addition of the specific P2Y11 agonist NF546. Altogether, these data suggest that Panx1 is part of the P2Y11/AKAP5/AC5/PKA/CaV1.2 signaling module in arterial myocytes. This Panx1‐led complex modulates L‐type CaV1.2 activity and vascular reactivity in response to diabetic hyperglycemic conditions. Thus, Panx1 could be a new therapeutic target to treat vascular complications during diabetes.